Beam Therapeutics (BEAM) Share-based Compensation (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Share-based Compensation data on file, last reported at $19.0 million in Q1 2026.

• On a quarterly basis, Share-based Compensation fell 28.63% year-over-year to $19.0 million in Q1 2026; TTM through Mar 2026 was $96.4 million, a 18.16% decrease from a year earlier, with the FY2025 full-year figure at $94.2 million, down 21.89% from the prior year.
• Share-based Compensation for Q1 2026 stood at $19.0 million, down from $20.4 million in the prior quarter.
• Over the last five years, Share-based Compensation for BEAM reached as high as $97.6 million in Q3 2024 and fell as low as $18.0 million in Q1 2022.
• Historically, Share-based Compensation has averaged $37.9 million across 5 years, with a median of $26.3 million in 2023.
• Across the five-year window, Share-based Compensation jumped 288.02% in 2022 and sank 53.31% in 2023, its largest moves.
• Year by year, Share-based Compensation stood at $48.4 million in 2022, then sank by 53.31% to $22.6 million in 2023, then soared by 33.61% to $30.2 million in 2024, then slumped by 32.33% to $20.4 million in 2025, then slipped by 6.87% to $19.0 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $19.0 million in Q1 2026, $20.4 million in Q4 2025, and $84.2 million in Q3 2025.